The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).
Eligibility
Sex
ALL
Min age
6 Years
Max age
24 Years
Healthy volunteers
No
Inclusion Criteria:
Patients will be eligible for participation if all the following are true.
* Aged 6 - 24 years.
* Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
* Primary diagnosis of ADHD (all types).
* Starting Methylphenidate (excluding immediate release forms) treatment.
Exclusion Criteria:
Patients will be excluded from participation if any of the following are true.
* Co-occurring psychotic, bipolar or eating disorders.
* Significant risk of suicide.
* An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders.
* Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.
* Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study
* History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.
Primary outcome measure(s)
Change in ADHD symptom severity — Baseline and 1, 2, 3, and 4 weeks post-baseline Strengths and Weaknesses of Attention-Deficit/Hyperactivity Symptoms and Normal Behavior Scale (SWAN) Rating Scale for ADHD. Score range = -90 to +90, with higher scores indicative of worse outcome.
Side effect frequency and severity — 1, 2, 3, and 4 weeks post-baseline CADDRA ADHD Medication and Side Effect Form
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.